Valerio Therapeutics Société anonyme (EPA:ALVIO)
France · Delayed Price · Currency is EUR 0.7510
+0.0100 (1.35%)
Aug 3, 2026, 3:08 PM CET
EPA:ALVIO Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1.05 | 1.18 | 6.82 | 14.59 | 17.89 |
Cash & Short-Term Investments | 1.05 | 1.18 | 6.82 | 14.59 | 17.89 |
Cash Growth | -10.61% | -82.72% | -53.26% | -18.45% | 23.16% |
Accounts Receivable | 1.94 | 1.72 | 1.89 | 1.47 | 8.53 |
Other Receivables | 1.64 | 1.67 | 2.99 | 3.78 | 2.27 |
Receivables | 3.57 | 3.39 | 4.88 | 5.25 | 10.8 |
Prepaid Expenses | 0.15 | - | 1.17 | 0.29 | 1.45 |
Other Current Assets | - | - | 0.13 | 0.45 | -0 |
Total Current Assets | 4.78 | 4.57 | 13 | 20.58 | 30.13 |
Property, Plant & Equipment | 1.27 | 1.17 | 1.53 | 1.89 | 2.24 |
Goodwill | 8.17 | 11.97 | 18.06 | 18.06 | 18.06 |
Other Intangible Assets | -3.26 | -3.26 | - | - | - |
Long-Term Deferred Charges | 3.26 | 3.26 | 2.47 | 2.47 | 2.47 |
Other Long-Term Assets | 1.02 | 0.22 | 0.22 | 0.09 | 0.16 |
Total Assets | 15.23 | 17.93 | 35.27 | 43.09 | 53.06 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.28 | 5.25 | 2.46 | 3.45 | 2.83 |
Accrued Expenses | 0.85 | 1.71 | 2.62 | 1.81 | 0.59 |
Short-Term Debt | 0.71 | 3.13 | 2 | 0.05 | - |
Current Portion of Long-Term Debt | 0.92 | 7.3 | 1.45 | 1 | 2.95 |
Current Portion of Leases | 0.16 | 0.33 | 0.33 | 0.34 | 0.47 |
Current Income Taxes Payable | 0.94 | 0.63 | 0.58 | 0.48 | 0.21 |
Other Current Liabilities | 0.45 | - | 1.69 | 0.02 | - |
Total Current Liabilities | 6.3 | 18.34 | 11.13 | 7.15 | 7.06 |
Long-Term Debt | 6.23 | 5.63 | 6.91 | 8.1 | 5.08 |
Long-Term Leases | 0.3 | 0.18 | 0.31 | 0.65 | 1.43 |
Pension & Post-Retirement Benefits | 0.04 | 0.03 | 0.11 | 0.17 | 0.61 |
Long-Term Deferred Tax Liabilities | - | - | - | - | 0.2 |
Other Long-Term Liabilities | 0.28 | 2.01 | 2.01 | 4.75 | 5.74 |
Total Liabilities | 13.16 | 26.19 | 20.47 | 20.82 | 20.12 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 4.99 | 21.61 | 38.59 | 27.88 | 23 |
Additional Paid-In Capital | 29.12 | 15.69 | 28.99 | 27.71 | 24.58 |
Retained Earnings | -31.94 | -46.51 | -53.14 | -33.43 | -5.94 |
Treasury Stock | - | -0.04 | -0.06 | -0.08 | -0.18 |
Comprehensive Income & Other | -0.1 | 0.31 | 0.43 | 0.19 | -8.52 |
Total Common Equity | 2.08 | -8.93 | 14.81 | 22.27 | 32.94 |
Minority Interest | - | 0.67 | - | - | - |
Shareholders' Equity | 2.08 | -8.27 | 14.81 | 22.27 | 32.94 |
Total Liabilities & Equity | 15.23 | 17.93 | 35.27 | 43.09 | 53.06 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 8.31 | 16.56 | 11 | 10.13 | 9.93 |
Net Cash (Debt) | -7.26 | -15.38 | -4.18 | 4.45 | 7.95 |
Net Cash Growth | - | - | - | -44.02% | -3.79% |
Net Cash Per Share | -0.03 | -0.10 | -0.03 | 0.04 | 0.09 |
Filing Date Shares Outstanding | 499.45 | 153.88 | 154 | 110.93 | 111.08 |
Total Common Shares Outstanding | 499.45 | 153.88 | 154 | 110.93 | 91.57 |
Working Capital | -1.52 | -13.77 | 1.87 | 13.43 | 23.07 |
Book Value Per Share | 0.00 | -0.06 | 0.10 | 0.20 | 0.36 |
Tangible Book Value | -2.84 | -17.64 | -3.25 | 4.21 | 14.88 |
Tangible Book Value Per Share | -0.01 | -0.11 | -0.02 | 0.04 | 0.16 |